Sharon E Frey1, Mari Rose Aplasca-De Los Reyes2, Humberto Reynales3, Nancy Nazaire Bermal4, Uwe Nicolay4, Vas Narasimhan4, Eduardo Forleo-Neto4, Ashwani Kumar Arora5. 1. Division of Infectious Diseases, Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, USA. 2. Research Institute for Tropical Medicine, Alabang, Muntinlupa City, Philippines. 3. Centro de Atención e Investigación Médica (CAIMED), Bogotá, Colombia. 4. Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA. 5. Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA. Electronic address: ashwani_kumar.arora@novartis.com.
Abstract
AIM: Adjuvanted influenza vaccines can overcome the poor antibody response of conventional non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity, safety and clinical effectiveness of an MF59(®)-adjuvanted trivalent influenza vaccine (aTIV) compared with a non-adjuvanted vaccine (TIV) in subjects ≥65 years old, with or without co-morbidities. METHODS:In 2010-2011, subjects (N=7082) were randomized to receive one dose of aTIV or TIV. Co-primary objectives were to assess lot-to-lot consistency of aTIV, non-inferiority, superiority and immunogenicity 22 days after vaccination. Clinical effectiveness, reactogenicity and serious adverse events were monitored up to Day 366. RESULTS: The immunological equivalence of three lots of aTIV was demonstrated. aTIV was not only non-inferior to TIV but also elicited significantly higher antibody responses at Day 22 than TIV against all homologous and heterologous strains, even in subjects with co-morbidities. Superiority was not established. Reactogenicity was higher in the aTIV group, but reactions were mild to moderate and transient. CONCLUSIONS: aTIV elicited a significantly higher antibody response than TIV, especially against A/H3N2 strains, although superiority by pre-defined criteria was not formally met. The study demonstrates potential immunological benefits of MF59-adjuvanted influenza vaccines for the elderly. This trial was registered with www.clinicaltrials.gov (NCT01162122).
RCT Entities:
AIM: Adjuvanted influenza vaccines can overcome the poor antibody response of conventional non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity, safety and clinical effectiveness of an MF59(®)-adjuvanted trivalent influenza vaccine (aTIV) compared with a non-adjuvanted vaccine (TIV) in subjects ≥65 years old, with or without co-morbidities. METHODS: In 2010-2011, subjects (N=7082) were randomized to receive one dose of aTIV or TIV. Co-primary objectives were to assess lot-to-lot consistency of aTIV, non-inferiority, superiority and immunogenicity 22 days after vaccination. Clinical effectiveness, reactogenicity and serious adverse events were monitored up to Day 366. RESULTS: The immunological equivalence of three lots of aTIV was demonstrated. aTIV was not only non-inferior to TIV but also elicited significantly higher antibody responses at Day 22 than TIV against all homologous and heterologous strains, even in subjects with co-morbidities. Superiority was not established. Reactogenicity was higher in the aTIV group, but reactions were mild to moderate and transient. CONCLUSIONS:aTIV elicited a significantly higher antibody response than TIV, especially against A/H3N2 strains, although superiority by pre-defined criteria was not formally met. The study demonstrates potential immunological benefits of MF59-adjuvanted influenza vaccines for the elderly. This trial was registered with www.clinicaltrials.gov (NCT01162122).
Authors: Alex B Ryder; Linda Buonocore; Leatrice Vogel; Raffael Nachbagauer; Florian Krammer; John K Rose Journal: J Virol Date: 2014-12-24 Impact factor: 5.103
Authors: Christopher Robson; Sai Rupa Baskar; Robert Booy; Patricia E Ferguson; Nicole Gilroy; Jen Kok; Indy Sandaradura; Dominic Dwyer Journal: Aust Prescr Date: 2019-04-01
Authors: Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Ann L Oberg; Michael T Zimmermann; Diane E Grill; Gregory A Poland Journal: Front Immunol Date: 2016-11-02 Impact factor: 7.561
Authors: Gregory A Poland; Jennifer A Whitaker; Caroline M Poland; Inna G Ovsyannikova; Richard B Kennedy Journal: Curr Opin Virol Date: 2016-03-30 Impact factor: 7.090
Authors: Andrew J Dunning; Carlos A DiazGranados; Timothy Voloshen; Branda Hu; Victoria A Landolfi; H Keipp Talbot Journal: Clin Vaccine Immunol Date: 2016-01-13